Mohamed E. El Beeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohamed E. El Beeh has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Mohamed Fawzy Ramadan
Umm Al-Qura University
5 shared publications Sameer H. Qari
Biology Department, El-Jumum University College, Umm Al-Qura University, Makkah, Saudi Arabia
5 shared publicationsAshraf A. El-Badawi
Biology Department, El-Jumum University College, Umm Al-Qura University, Makkah, Saudi Arabia
3 shared publications- Hassan Ih El-Sayyad
Department of Zoology, Faculty of Science, Mansoura University, Mansoura, Egypt
3 shared publications Wessam M. Filfilan
Biology Department, El-Jumum University College, Umm Al-Qura University, Makkah, Saudi Arabia
3 shared publications- Wessam Mansour Filfilan
Department of Biology, Jamoum University College, Umm Al-Qura University, Makkah 21955, Saudi Arabia
3 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 11 (11) , 301
Self-Brought Antibiotics and Their WHO AWaRe Composition at the Hajj: A Two-Season, Photo-Verified Pilot Study
Pilgrims bring their own medicines to the Hajj, but the antibiotics they carry have been described only through self-report. This pilot tested whether a photo-verified inventory of the medicine bag that pilgrims have with them is practicable, and estimated the carriage and WHO Access, Watch, Reserve (AWaRe) composition of self-brought antibiotics. International pilgrims were interviewed in Makkah, Mina and Arafat during Hajj 1445 AH (2024) and 1446 AH (2025), and every package in their bag was photographed. Of 60 pilgrims from 17 countries, 50 made a bag available; together, these held 190 items, including 48 systemic antibiotics of eleven agents. Thirty-four carried at least one antibiotic (68.0% of inventoried pilgrims, 95% CI 54.2–79.2). Access agents made up 58.3% of the antibiotics (95% CI 44.3–71.2), not significantly below the 70% target (p = 0.084); none were Reserve. Of the antibiotics, 27.1% had been bought without a prescription and 85.4% were incomplete packs. In a post hoc analysis resting on few items, the Access share rose as national prescription enforcement weakened, opposite to the exploratory hypothesis; this gradient is unreliable. Photo-verified inventory is practicable among pilgrims who agree to be interviewed, and these imprecise estimates can inform an adequately powered multinational study.
- 23 October 2026
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 11 (11) , 301
Open AccessSelf-Brought Antibiotics and Their WHO AWaRe Composition at the Hajj: A Two-Season, Photo-Verified Pilot Study
Pilgrims bring their own medicines to the Hajj, but the antibiotics they carry have been described only through self-report. This pilot tested whether a photo-verified inventory of the medicine bag that pilgrims have with them is practicable, and estimated the carriage and WHO Access, Watch, Reserve (AWaRe) composition of self-brought antibiotics. International pilgrims were interviewed in Makkah, Mina and Arafat during Hajj 1445 AH (2024) and 1446 AH (2025), and every package in their bag was photographed. Of 60 pilgrims from 17 countries, 50 made a bag available; together, these held 190 items, including 48 systemic antibiotics of eleven agents. Thirty-four carried at least one antibiotic (68.0% of inventoried pilgrims, 95% CI 54.2–79.2). Access agents made up 58.3% of the antibiotics (95% CI 44.3–71.2), not significantly below the 70% target (p = 0.084); none were Reserve. Of the antibiotics, 27.1% had been bought without a prescription and 85.4% were incomplete packs. In a post hoc analysis resting on few items, the Access share rose as national prescription enforcement weakened, opposite to the exploratory hypothesis; this gradient is unreliable. Photo-verified inventory is practicable among pilgrims who agree to be interviewed, and these imprecise estimates can inform an adequately powered multinational study.
- 7 October 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 374 (Pt 2) , 122467
Aqueous Hellenia speciosa rhizome extract attenuates hepatic injury in high-fat diet/streptozotocin-induced diabetic rats
- 7 October 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 374 (Pt 2) , 122467
Aqueous Hellenia speciosa rhizome extract attenuates hepatic injury in high-fat diet/streptozotocin-induced diabetic rats
- 27 September 2026
- Published by Taylor & Francis in Drug and Chemical Toxicology
- Vol. 49 (6) , 1629-1641
Subacute oral glyphosate induces dose-dependent renal injury in male mice ( Mus musculus )
1. Glyphosate [N-(phosphonomethyl)glycine] is the most extensively used herbicide in the world; the volume of glyphosate-based herbicides (GBHs) applied has risen roughly 100-fold since their intro...
- 27 September 2026
- Published by Taylor & Francis in Drug and Chemical Toxicology
- Vol. 49 (6) , 1629-1641
Subacute oral glyphosate induces dose-dependent renal injury in male mice ( Mus musculus )
1. Glyphosate [N-(phosphonomethyl)glycine] is the most extensively used herbicide in the world; the volume of glyphosate-based herbicides (GBHs) applied has risen roughly 100-fold since their intro...
- 2 July 2026
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 41 (1)
Supra-additive neuroprotective effects of berberine–metformin combination in diabetic encephalopathy: Chou–Talalay synergy quantification, AMPK–Nrf2 axis modulation, and pharmacokinetic verification
Type 2 diabetes mellitus (T2DM) increases the risk of hippocampal neurodegeneration and cognitive decline. Berberine and metformin independently activate AMPK and may engage Nrf2-mediated antioxidant defenses, yet their combined neuroprotective interaction has not been formally quantified using validated synergy frameworks, nor has its pharmacokinetic basis been verified. Streptozotocin-nicotinamide diabetic rats were allocated to twelve groups (n = 13/group) receiving berberine (50, 100, 150 mg/kg/day) or metformin (100, 200, 300 mg/kg/day) monotherapy, fixed-ratio 1:2 combinations, or vehicle controls (including a non-diabetic combination group) orally for six weeks. The novel object recognition (NOR) discrimination index served as the predefined primary endpoint for Chou-Talalay combination index (CI) analysis. Hippocampal mechanistic (n = 6/group) and satellite LC-MS/MS pharmacokinetic (n = 6/group) analyses were performed. Diabetes impaired NOR discrimination index (37.2 ± 3.8% vs. 68.4 ± 3.2%; p < 0.001). The reference combination (100 + 200 mg/kg) restored NOR to 67.1 ± 3.6% with CI = 0.65 (95% CI: 0.43-0.91), synergism maintained across the full effect range. All six neuroinflammatory endpoints achieved Benjamini-Hochberg-corrected significance (p_adj = 0.006-0.043; Tier 2). Non-diabetic combination animals showed reduced AMPK activation magnitude (1.53 vs. 2.31-fold; P_adj = 0.067; Tier 3, hypothesis-generating). LC-MS/MS verified bioequivalent drug exposure. Berberine-metformin co-treatment is associated with CI-quantified supra-additive recognition memory recovery in diabetic encephalopathy, with neuroinflammatory suppression as the most statistically robust mechanistic correlate. Pharmacokinetic findings are consistent with a pharmacodynamic rather than pharmacokinetic basis. Causal involvement of the AMPK-Nrf2 axis remains correlative pending direct loss-of-function validation.
- 2 July 2026
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 41 (1)
Supra-additive neuroprotective effects of berberine–metformin combination in diabetic encephalopathy: Chou–Talalay synergy quantification, AMPK–Nrf2 axis modulation, and pharmacokinetic verification
Type 2 diabetes mellitus (T2DM) increases the risk of hippocampal neurodegeneration and cognitive decline. Berberine and metformin independently activate AMPK and may engage Nrf2-mediated antioxidant defenses, yet their combined neuroprotective interaction has not been formally quantified using validated synergy frameworks, nor has its pharmacokinetic basis been verified. Streptozotocin-nicotinamide diabetic rats were allocated to twelve groups (n = 13/group) receiving berberine (50, 100, 150 mg/kg/day) or metformin (100, 200, 300 mg/kg/day) monotherapy, fixed-ratio 1:2 combinations, or vehicle controls (including a non-diabetic combination group) orally for six weeks. The novel object recognition (NOR) discrimination index served as the predefined primary endpoint for Chou-Talalay combination index (CI) analysis. Hippocampal mechanistic (n = 6/group) and satellite LC-MS/MS pharmacokinetic (n = 6/group) analyses were performed. Diabetes impaired NOR discrimination index (37.2 ± 3.8% vs. 68.4 ± 3.2%; p < 0.001). The reference combination (100 + 200 mg/kg) restored NOR to 67.1 ± 3.6% with CI = 0.65 (95% CI: 0.43-0.91), synergism maintained across the full effect range. All six neuroinflammatory endpoints achieved Benjamini-Hochberg-corrected significance (p_adj = 0.006-0.043; Tier 2). Non-diabetic combination animals showed reduced AMPK activation magnitude (1.53 vs. 2.31-fold; P_adj = 0.067; Tier 3, hypothesis-generating). LC-MS/MS verified bioequivalent drug exposure. Berberine-metformin co-treatment is associated with CI-quantified supra-additive recognition memory recovery in diabetic encephalopathy, with neuroinflammatory suppression as the most statistically robust mechanistic correlate. Pharmacokinetic findings are consistent with a pharmacodynamic rather than pharmacokinetic basis. Causal involvement of the AMPK-Nrf2 axis remains correlative pending direct loss-of-function validation.
- Open Access
Alpha-Lipoic Acid and Metformin Combination Therapy Synergistically Activate Nrf2-AMPK Signaling Pathways to Ameliorate Cognitive Dysfunction in Type 2 Diabetic Encephalopathy: A Preclinical Study
Diabetic encephalopathy affects over 40% of diabetic patients globally, yet effective treatments remain critically limited. This study investigated the synergistic neuroprotective potential of alpha-lipoic acid (ALA) and metformin through the coordinated activation of Nrf2 and AMPK signaling pathways in type 2 diabetes mellitus (T2DM)-induced encephalopathy. Using a clinically relevant streptozotocin-nicotinamide-induced T2DM rat model, sixty male Sprague–Dawley rats were randomly assigned to five groups: control, diabetic, ALA-treated (300 mg/kg), metformin-treated (50 mg/kg), and combination-treated groups over eight weeks. Combination therapy produced statistically validated synergistic effects with significant interaction terms (p < 0.01) across all evaluated parameters. Nuclear Nrf2 translocation increased 3.9-fold and AMPK phosphorylation rose 3.2-fold compared to monotherapies, surpassing mathematical additivity. Mitochondrial function was remarkably restored, with ATP production increasing to 92% of control levels. Cognitive performance was normalized, with spatial memory approaching control values. Combination index analysis (CI < 1.0) confirmed true synergistic interactions across molecular, cellular, and behavioral endpoints. These findings establish a novel convergent mechanism providing compelling evidence for combination ALA–metformin therapy as an innovative treatment strategy for diabetes-associated neurodegeneration.
Open AccessAlpha-Lipoic Acid and Metformin Combination Therapy Synergistically Activate Nrf2-AMPK Signaling Pathways to Ameliorate Cognitive Dysfunction in Type 2 Diabetic Encephalopathy: A Preclinical Study
Diabetic encephalopathy affects over 40% of diabetic patients globally, yet effective treatments remain critically limited. This study investigated the synergistic neuroprotective potential of alpha-lipoic acid (ALA) and metformin through the coordinated activation of Nrf2 and AMPK signaling pathways in type 2 diabetes mellitus (T2DM)-induced encephalopathy. Using a clinically relevant streptozotocin-nicotinamide-induced T2DM rat model, sixty male Sprague–Dawley rats were randomly assigned to five groups: control, diabetic, ALA-treated (300 mg/kg), metformin-treated (50 mg/kg), and combination-treated groups over eight weeks. Combination therapy produced statistically validated synergistic effects with significant interaction terms (p < 0.01) across all evaluated parameters. Nuclear Nrf2 translocation increased 3.9-fold and AMPK phosphorylation rose 3.2-fold compared to monotherapies, surpassing mathematical additivity. Mitochondrial function was remarkably restored, with ATP production increasing to 92% of control levels. Cognitive performance was normalized, with spatial memory approaching control values. Combination index analysis (CI < 1.0) confirmed true synergistic interactions across molecular, cellular, and behavioral endpoints. These findings establish a novel convergent mechanism providing compelling evidence for combination ALA–metformin therapy as an innovative treatment strategy for diabetes-associated neurodegeneration.
- Open Access
Hepatoprotective Effects of Glycyrrhiza glabra in Diabetic Male Rats: Addressing Liver Function, Oxidative Stress, and Histopathological Changes
Diabetes mellitus is a chronic metabolic disorder that often leads to hepatic complications, including oxidative stress, inflammation, and structural damage, highlighting the need for effective hepatoprotective agents. Glycyrrhiza glabra (licorice), known for its bioactive compounds with medicinal properties, has gained attention as a potential therapeutic option. This study investigated its hepatoprotective effects in a diabetic rat model. Diabetes was induced using streptozotocin, and animals were divided into four groups: a healthy control, a non-diabetic group treated with Glycyrrhiza glabra extract, an untreated diabetic group, and a diabetic group receiving daily doses of the extract. Liver function was assessed through serum enzyme levels (ALT, AST, and ALP), while oxidative stress markers, including malondialdehyde (MDA) and glutathione (GSH), were analyzed. Histological examination was conducted to evaluate inflammation, fibrosis, and fatty degeneration. Treatment with Glycyrrhiza glabra significantly improved liver function in diabetic rats, as evidenced by lower ALT, AST, and ALP levels compared to untreated diabetic rats (p < 0.05), suggesting hepatocyte protection through its antioxidant and anti-inflammatory properties. Favorable changes in oxidative stress markers were observed, with lower MDA levels indicating reduced lipid peroxidation and higher GSH activity reflecting enhanced antioxidant defense. Histological analysis confirmed these protective effects, showing reduced inflammation, diminished fatty degeneration, and overall structural improvements. These findings highlight the hepatoprotective potential of Glycyrrhiza glabra, suggesting it may be a promising therapeutic agent for managing hepatic complications associated with diabetes mellitus, though further research with larger sample sizes and mechanistic studies is needed for confirmation.
Open AccessHepatoprotective Effects of Glycyrrhiza glabra in Diabetic Male Rats: Addressing Liver Function, Oxidative Stress, and Histopathological Changes
Diabetes mellitus is a chronic metabolic disorder that often leads to hepatic complications, including oxidative stress, inflammation, and structural damage, highlighting the need for effective hepatoprotective agents. Glycyrrhiza glabra (licorice), known for its bioactive compounds with medicinal properties, has gained attention as a potential therapeutic option. This study investigated its hepatoprotective effects in a diabetic rat model. Diabetes was induced using streptozotocin, and animals were divided into four groups: a healthy control, a non-diabetic group treated with Glycyrrhiza glabra extract, an untreated diabetic group, and a diabetic group receiving daily doses of the extract. Liver function was assessed through serum enzyme levels (ALT, AST, and ALP), while oxidative stress markers, including malondialdehyde (MDA) and glutathione (GSH), were analyzed. Histological examination was conducted to evaluate inflammation, fibrosis, and fatty degeneration. Treatment with Glycyrrhiza glabra significantly improved liver function in diabetic rats, as evidenced by lower ALT, AST, and ALP levels compared to untreated diabetic rats (p < 0.05), suggesting hepatocyte protection through its antioxidant and anti-inflammatory properties. Favorable changes in oxidative stress markers were observed, with lower MDA levels indicating reduced lipid peroxidation and higher GSH activity reflecting enhanced antioxidant defense. Histological analysis confirmed these protective effects, showing reduced inflammation, diminished fatty degeneration, and overall structural improvements. These findings highlight the hepatoprotective potential of Glycyrrhiza glabra, suggesting it may be a promising therapeutic agent for managing hepatic complications associated with diabetes mellitus, though further research with larger sample sizes and mechanistic studies is needed for confirmation.
- Open Access
- 3 February 2025
- Published by Elsevier in Electronic Journal of Biotechnology
- Vol. 74, 54-72
Exploring the multifaceted bioactivities of silver nanoparticles synthesized from red algae Hypnea pannosa: Antimicrobial, antibiofilm, and insecticidal potentials
- 3 February 2025
- Published by Elsevier in Electronic Journal of Biotechnology
- Vol. 74, 54-72
Open AccessExploring the multifaceted bioactivities of silver nanoparticles synthesized from red algae Hypnea pannosa: Antimicrobial, antibiofilm, and insecticidal potentials
- Open Access
- 14 November 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-16
Anticancer, antimicrobial, insecticidal and molecular docking of sarcotrocheliol and cholesterol from the marine soft coral Sarcophyton Trocheliophorum
The anticancer, antimicrobial, and insecticidal activities of sarcotrocheliol (1) and cholesterol (2) obtained from the soft coral Sarcophyton trocheliophorum (S. trocheliophorum) were intensively studied. According to this study, both compounds 1 and 2 showed potential cytotoxicity towards the human colorectal carcinomaHCT-116 (IC50 10.4, 11.8 µg/mL) and human liver carcinoma HepG2 cell lines (IC50 8.8, 12.0 µg/mL), respectively. Compounds 1 and 2 were evaluated as potential inhibitors of caspase-3, a member of the cysteine protease family, which is considered a key enzyme in inducing cell apoptosis. Results showed that compounds 1 and 2 have induced apoptosis via up-regulation of caspase-3. Sarcotrocheliol (1) displayed antimicrobial activity against P. aeruginosa (15 mm), B. subtilis (15 mm), M. luteus (14 mm) and C. albicans (15 mm), with a MIC of 1.5 µg/mL against the reported test microorganisms. On the other hand, cholesterol (2) showed less activity towards P. aeruginosa (10 mm), B. subtilis (14 mm), S. aureus (12 mm) and C. albicans (10 mm) with MICs of 3.0, 1.5, 1.5 and 3.0 µg/mL against the tested microorganisms, respectively. Larvicidal activity revealed that compounds 1 and 2 induced remarkable toxicity against the third instar larvae of the mosquito, Culex pipiens even at concentration of 2 ppm. Adulticidal activity data showed that tested compounds are distinctly potent toxicants against the housefly, Musca domestica adult females. Overall, compound 2induced much more insecticidal activity than 1, and M. domestica adult females were more sensitive to tested compounds than C. pipiens larvae. Computationally, Density Functional Theory (DFT) analyses revealed that compound 2 had a higher dipole moment and lower band gap energy when compared to compound 1. So, compounds 2 is chemically more reactive and less stable than compound 1. According to the molecular docking study against PDB IDs: 3KJF, 5UHF and 1ACJ, compounds 1 and 2 demonstrated their activity mode as anticancer, antimicrobial, and insecticidal agents. The compounds exerted many interactions and showed high binding to the proteins, recognizing their potential as drug candidates with broad bioactivities.
- 14 November 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-16
Open AccessAnticancer, antimicrobial, insecticidal and molecular docking of sarcotrocheliol and cholesterol from the marine soft coral Sarcophyton Trocheliophorum
The anticancer, antimicrobial, and insecticidal activities of sarcotrocheliol (1) and cholesterol (2) obtained from the soft coral Sarcophyton trocheliophorum (S. trocheliophorum) were intensively studied. According to this study, both compounds 1 and 2 showed potential cytotoxicity towards the human colorectal carcinomaHCT-116 (IC50 10.4, 11.8 µg/mL) and human liver carcinoma HepG2 cell lines (IC50 8.8, 12.0 µg/mL), respectively. Compounds 1 and 2 were evaluated as potential inhibitors of caspase-3, a member of the cysteine protease family, which is considered a key enzyme in inducing cell apoptosis. Results showed that compounds 1 and 2 have induced apoptosis via up-regulation of caspase-3. Sarcotrocheliol (1) displayed antimicrobial activity against P. aeruginosa (15 mm), B. subtilis (15 mm), M. luteus (14 mm) and C. albicans (15 mm), with a MIC of 1.5 µg/mL against the reported test microorganisms. On the other hand, cholesterol (2) showed less activity towards P. aeruginosa (10 mm), B. subtilis (14 mm), S. aureus (12 mm) and C. albicans (10 mm) with MICs of 3.0, 1.5, 1.5 and 3.0 µg/mL against the tested microorganisms, respectively. Larvicidal activity revealed that compounds 1 and 2 induced remarkable toxicity against the third instar larvae of the mosquito, Culex pipiens even at concentration of 2 ppm. Adulticidal activity data showed that tested compounds are distinctly potent toxicants against the housefly, Musca domestica adult females. Overall, compound 2induced much more insecticidal activity than 1, and M. domestica adult females were more sensitive to tested compounds than C. pipiens larvae. Computationally, Density Functional Theory (DFT) analyses revealed that compound 2 had a higher dipole moment and lower band gap energy when compared to compound 1. So, compounds 2 is chemically more reactive and less stable than compound 1. According to the molecular docking study against PDB IDs: 3KJF, 5UHF and 1ACJ, compounds 1 and 2 demonstrated their activity mode as anticancer, antimicrobial, and insecticidal agents. The compounds exerted many interactions and showed high binding to the proteins, recognizing their potential as drug candidates with broad bioactivities.
- Open Access
- 1 January 2024
- Published by Wiley in International Journal of Microbiology
- Vol. 2024 (1) , 7518368
Antimicrobial and Antibiofilm Activity of Monolaurin against Methicillin‐Resistant Staphylococcus aureus Isolated from Wound Infections
Background. Methicillin‐resistant Staphylococcus aureus (MRSA) is one of the major pathogens associated with life‐threatening infections, showing resistance to various antibiotics. This study aimed to assess the influence of monolaurin on biofilm‐forming MRSA. Methods. The agar dilution method determined the minimum inhibitory concentration (MIC) of monolaurin against MRSA isolates and explored its impact on the resistance profile of selected antibiotics. The assessment of combined therapy involving monolaurin and antibiotics was conducted using fractional inhibitory concentration (FIC). The tissue culture plate strategy appraised monolaurin’s antibiofilm activity and its inhibitory concentration (IC50), with assessment via scanning electron microscopy. Reverse transcription polymerase chain reaction (RT‐PCR) discerned a monolaurin effect on the expression of the icaD gene. Results. Monolaurin exhibited MIC values ranging from 500 to 2000 μg/mL. FIC index showed a synergistic effect of monolaurin with β‐lactam antibiotics ranging from 0.0039 to 0.25 (p < 0.001). Among the 103 investigated MRSA isolates, 44 (44.7%) displayed moderate biofilm formation, while 59 (55.3%) were strong biofilm producers. Antibiofilm activity demonstrated concentration dependence, confirming monolaurin’s capacity to inhibit biofilm formation and exhibited strong eradicating effects against preformed MRSA biofilms with IC50 values of 203.6 μg/mL and 379.3 μg/mL, respectively. Scanning electron microscope analysis revealed reduced cell attachments and diminished biofilm formation compared to the control. The expression levels of the icaD gene were remarkably reduced at monolaurin concentrations of 250 and 500 μg/mL. Conclusion. Monolaurin had significant inhibitory effects on MRSA pre‐existing biofilms as well as biofilm development. So, it can be employed in the treatment of severe infections, particularly those associated with biofilm formation including catheter‐associated infections.
- 1 January 2024
- Published by Wiley in International Journal of Microbiology
- Vol. 2024 (1) , 7518368
Open AccessAntimicrobial and Antibiofilm Activity of Monolaurin against Methicillin‐Resistant Staphylococcus aureus Isolated from Wound Infections
Background. Methicillin‐resistant Staphylococcus aureus (MRSA) is one of the major pathogens associated with life‐threatening infections, showing resistance to various antibiotics. This study aimed to assess the influence of monolaurin on biofilm‐forming MRSA. Methods. The agar dilution method determined the minimum inhibitory concentration (MIC) of monolaurin against MRSA isolates and explored its impact on the resistance profile of selected antibiotics. The assessment of combined therapy involving monolaurin and antibiotics was conducted using fractional inhibitory concentration (FIC). The tissue culture plate strategy appraised monolaurin’s antibiofilm activity and its inhibitory concentration (IC50), with assessment via scanning electron microscopy. Reverse transcription polymerase chain reaction (RT‐PCR) discerned a monolaurin effect on the expression of the icaD gene. Results. Monolaurin exhibited MIC values ranging from 500 to 2000 μg/mL. FIC index showed a synergistic effect of monolaurin with β‐lactam antibiotics ranging from 0.0039 to 0.25 (p < 0.001). Among the 103 investigated MRSA isolates, 44 (44.7%) displayed moderate biofilm formation, while 59 (55.3%) were strong biofilm producers. Antibiofilm activity demonstrated concentration dependence, confirming monolaurin’s capacity to inhibit biofilm formation and exhibited strong eradicating effects against preformed MRSA biofilms with IC50 values of 203.6 μg/mL and 379.3 μg/mL, respectively. Scanning electron microscope analysis revealed reduced cell attachments and diminished biofilm formation compared to the control. The expression levels of the icaD gene were remarkably reduced at monolaurin concentrations of 250 and 500 μg/mL. Conclusion. Monolaurin had significant inhibitory effects on MRSA pre‐existing biofilms as well as biofilm development. So, it can be employed in the treatment of severe infections, particularly those associated with biofilm formation including catheter‐associated infections.
- 9 September 2023
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 646, 123385
Investigating the superiority of chitosan/D-alpha-tocopheryl polyethylene glycol succinate binary coated bilosomes in promoting the cellular uptake and anti-SARS-CoV-2 activity of polyphenolic herbal drug candidate
- 9 September 2023
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 646, 123385
Investigating the superiority of chitosan/D-alpha-tocopheryl polyethylene glycol succinate binary coated bilosomes in promoting the cellular uptake and anti-SARS-CoV-2 activity of polyphenolic herbal drug candidate